D9268.PDF

Rev. sci. tech. Off. int. Epiz., 1999,18 (3), 638-647
Classical swine fever: the European experience
and a guide for infected areas
J. V a n d e p u t t e & G. Chappuis
( 1 )
(2)
(1 ) Merial, 29 avenue Tony Garnier, 69007 Lyons, France
(2) Merial, 254 rue Marcel Mérieux, 69007 Lyons, France
Submitted for publication: 31 March 1999
Accepted for publication: 28 July 1999
Summary
Classical swine fever (CSF) (hog cholera) virus infection is still of world-wide
concern, either because of the direct effects of the disease on swine breeding in
areas where the virus is epizootic or enzootic, or as a threat in areas where the
virus has been eradicated.
The authors provide an overview of the characteristics of the disease. Special
emphasis is placed on the chronic form of disease, particularly in the late stages
of eradication programmes.
In the early 1980s, the European Union (EU) was composed of countries which
were officially free of the disease (absence of infection and no vaccination) and
countries in which vaccination was either permitted or was compulsory. To
ensure free trade between the Member States, an eradication plan w a s agreed
upon and implemented. Initially, the plan consisted of a combination of
vaccination with the Chinese strain of the virus and slaughter and removal of
infected herds. Consequently, when the number of infected herds w a s low,
vaccination was abandoned and the control of CSF was conducted exclusively by
eradication (removal and slaughter). The United Kingdom, Austria, Denmark,
Ireland, Luxembourg, Finland and Sweden ceased vaccination before 1980. In the
other countries, vaccination was useful in controlling the last epidemics and w a s
finally ceased as follows: France in 1983, the Netherlands in 1986, Belgium, Spain
and Greece in 1988, Germany in 1989 and Italy in 1990. From 1990 onwards, no
vaccination against CSF has been performed in the EU.
N e w techniques for the diagnosis of CSF (for example, the enzyme-linked
immunosorbent assay based on the detection of the p125 antigen of the virus)
have been shown to be of value in the early detection of infected animals.
In enzootic areas, the use of vaccines based on the Chinese strain has been
successful. Vaccines with at least 100 P D of virus per dose are able to
significantly limit the replication of virulent virus in the tonsils. Consequently,
shedding of virus after infection can be reduced considerably. In heavily infected
areas, vaccination plays a crucial role. The European experience shows that
eradication may be achieved when vaccination with highly effective vaccines is
combined with effective identification of swine, movement control, early
diagnosis and the rapid elimination of infected herds.
50
Keywords
Classical swine fever - Diagnosis - European Union - Immunotolerance - Pestiviruses Pigs - Vaccination - Viruses.
639
Rev. sci. tech. Off. int. Epiz, 18 (3)
Introduction
but harbour and may excrète the virus for several months.
Wild boars can also act as a source of CSF infection (4, 11).
Classical swine fever (CSF) (hog choiera) remains of major
world-wide concern: in disease-free areas, introduction of the
disease is a constant threat and in contaminated areas,
eradication is the ultimate target. In both cases, the basic
characteristics of the CSF virus should be considered whether
attempting to maintain or achieve officiai freedom from CSF.
The disease is induced by a small enveloped RNA (ribonucleic
acid) virus named
classical
swine
fever virus
(CSFV),
belonging to the Flaviviridae family, genus Pestivirus
(36).
The virus leads to a systemic disease and provokes a variety of
symptoms in pigs. The most common signs in acute cases are
high température (> 40°C) and haemorrhages on the ears and
abdomen. Thèse symptoms are accompanied by respiratory
disease, enteric disease and central nervous disturbances.
Symptoms of the chronic form are much less typical, for
example, wasting and growth delay, particularly in cases
where the other symptoms considered as typical are absent.
Différences
in
strain
virulence
(9,
23,
34)
and
the
immunological status of the pig affected seem to be the major
factors influencing this varying clinical picture.
The présence of imrrtunotolerant animais persistently infected
with strains of low virulence may complicate early diagnosis
of the infection. Thèse animais do not express typical signs
and fail to produce antibodies ( 1 3 ) , making serological
diagnosis
problematic.
This
situation
is
similar
to
immunotolerance exhibited by ruminants infected with the
pestiviruses bovine virus diarrhoea virus (BVDV) of cattle and
border disease virus (BDV) of sheep (8). Van Oirschot and
Terpstra described the case of a carrier sow affected by a field
outbreak ( 5 0 ) . The animal gave birth to a litter of 11 piglets.
All piglets had CSFV in their pre-colostral plasma. Six piglets
were followed until death. At day two after birth, the piglets
had high virus titres in the plasma although ail had ingested
colostrum with a high antibody titre against CSFV. Finally, all
animais
developed
clinical signs, very late
after
birth,
commonly known as late onset'. Signs such as increasing
anorexia
and
depression,
conjunctivitis,
dermatitis
and
locomotion disturbances in varying degrees were noticed and
death ultimately occurred at 3 3 2 days after birth. None of the
piglets developed antibodies against CSFV. Vannier et al.
experimentally reproduced immunotolerant animals from
sows infected at 4 3 days of gestation ( 4 8 ) . A similar syndrome
was reproduced by Paton and Done in pigs congenitally
infected
infection
with
with
ruminant-type
CSFV
may
pestiviruses
occur
after
(38).
Chronic
infection
with
moderately virulent virus types or with strains which provoke
chronic cases of the disease (9, 3 4 ) . The virus may transiently
disappear from the sérum before reappearance of clinical
disease in a less clearly pronounced form. Such persistently
infected animais play an important role in the epidemiology of
the disease since the animais are not clearly affected clinically
Vaccines are an efficient tool to limit the circulation of the
virus in a swine population, on the condition that the vaccines
comply with high safety and efficacy requirements and are
properly applied.
In the early 1980s, some countries in Europe (United
Kingdom, Ireland and Denmark) were already completely free
of CSF: no vaccination or infection occurred in those
countries. However, other countries in Europe were infected
(5). This difference in health status of swine in regard to CSF
hampered free trade of swine and swine products within the
European Union (EU). Free trade of animais and animal
products within the EU is only possible if trade does not
represent a sanitary risk for countries which are free of
disease. As a consequence, sanitary status in regard to CSF
had to be harmonised within the EU.
Gaining officiai status of
freedom from classical swine
fever in the European Union
The EU commenced a generalised eradication plan in 1980, as
detailed and executed according to the Council Directive
80/217/EEC of 22January 1 9 8 0 (14) and Council Directives
80/1095 ( 1 5 ) , 80/1096 ( 1 6 ) , 80/1098 ( 1 7 ) , 80/1099 ( 1 8 ) ,
80/1100 (19) and 80/1101 (20) EEC of 11 November 1980.
Some important définitions of the Directives are reproduced
below:
1. Free of classical swine fever: no classical swine fever has
been diagnosed during the last 12 months.
2. Officially free of classical swine fever: no classical swine
fever has been diagnosed during the last 12 months, no swine
vaccinated against classical swine fever are present and
vaccination against classical swine fever has not been
authorised for at least 12 months.
3. Region: a country can be divided into well-defined régions
which may not all have an identical disease status. This system
does not automatically block a whole country for trade if only
some of thèse régions are affected by CSF ( 1 7 ) .
According to this legislation, all EU Member States were
expected to become officially free of CSF five years after
having presented an eradication plan.
In areas infected with CSF, vaccination was initially
intensified in order to cover the entire swine population. The
gênerai vaccination programme was accompanied by
well-defined measures to be taken in case of suspicion or
confirmation of the disease, financial measures for
640
Rev. sci. tech. Off. int. Epiz., 18 (3)
compensation, and procedures for identification and tracing
of infection. In the case of vaccination, only vaccines that were
produced from the Chinese strain and that had at least
100 P D
(protective dose 5 0 % ) were allowed (7, 3 0 ) .
Vaccination was performed under officiai control. Veterinary
Services controlled the vaccinations and assured that all
swine in the area concemed were duly vaccinated with the
officially-approved vaccines only. In parallel, presence of the
disease was controlled through a system of surveillance by
veterinarians and Veterinary Services. Every veterinarian had,
and still has, the obligation to declare every minor suspicion
of disease. After declaration, all movement of personnel,
goods and animals, to and from the herd concemed and a
defined area around the herd was stopped for a period
determined by the veterinary authorities. Cessation of
vaccination became possible in countries of the EU as
indicated in Table I.
5 0
Cessation of vaccination against
classical swine fever in the
European Union
Twelve months after the last country in the EU ceased
vaccination, the EU regarded itself as officially free from CSF.
After that date, the legislation according to the Directive
EEC/80/217 (14) was applied and in case of problems, special
measures were taken by decision of the Commission. Those
measures were based on tracing, identification, laboratory
analysis and eradication of herds and contact herds.
Table I
Cessation of vaccination for classical swine fever in the European
Union
M e m b e r State
Date of cessation of vaccination
Belgium
1 April 1988
Denmark
Before 1980*
Germany
1 January 1989
Greece
1 January 1988
Spain
1 July 1988
France
30 April 1983
Ireland
Before 1980*
Italy
1 January 1990
Luxembourg
Before 1980*
The Netherlands
15 July 1986
Portugal
1 July 1989
United Kingdom
Before 1980*
Austria
Before 1980*
Finland
Before 1980*
Sweden
Before 1980*
* Vaccination never applied or ceased before 1980
Source: Commission of the European Union
New disease outbreaks were experienced in Belgium in 1 9 9 0
and 1993/1994 (52). These outbreaks were eradicated
without vaccination, through an extensive network of
epidemio-surveillance, tracing of infection and contacts
between herds, laboratory analysis (viral and serological),
slaughter of animais in herds and preventive slaughter. The
following key topics were at the centre of control and
eradication:
- effective identification of all animals (43)
- movement control of animals and animal products within
the EU
- agreement and collaboration of transport organisations
- efficient
logistics
for
rendering
and
slaughter
of
animais (52)
- commitment of farmers and their organisations.
In the described situation, serological surveillance alone was
demonstrated to be insufficient for tracing the infection ( 2 6 ) .
This is a further confirmation of the problem posed by
chronically infected and immunotolerant pigs. Serological
examination must be complemented by virological
examination since persistently infected pigs are serologically
négative and virologically positive. Furthermore, tracing of
secondary outbreaks, clinical investigation of animais and
routine laboratory investigation of clinically sick animais for
CSF virus or antigens are essential (3). Epidemiological
investigation will provide important information about the
origin of outbreaks and possible existing risks. Genome
analysis of strains together with computer analysis, as
described by Greiser-Wilke et al, may be of considérable
assistance (22). The financial contribution of the authorities
must be stressed: farmers are compensated for ail animais
slaughtered within the framework of the eradication
programme by the Member States and the EU ( 5 1 ) .
Contacts by swine, transport vehicles and humans are the
main channels for transmission of CSF. Identification and
registration of animais are both essential in order to detect
contacts among farms. Tracing forwards and backwards is
necessary and probably the most difficult aspect of every
eradication attempt.
Germany was also confronted with CSF outbreaks in 1 9 9 3
and 1994, simultaneously with Belgium (39). Genome
analysis (32, 44) of the isolates provided interesting data
regarding the epidemiology. However, genomic différences
cannot be related to différent protective patterns among
virulent strains and vaccine strains.
In 1997, CSF reappeared in the Netherlands, Germany,
Belgium, Spain and Italy (1, 2, 3 5 ) . The genomic profile of the
isolates and tracing of infected and contact herds through the
identification system revealed that all these epidemics were
probably linked. Authorities in Belgium were successful in
rapidly eradicating the seven infected herds and fifty-five
contact herds as a preventive measure. As a consequence, the
641
Rev. sci. tech. Off. int Epiz.. 18 (3)
country regained status of officiai freedom from CSF within
4 0 days (35). Eradication was equally successful in Italy.
In the EU, the control of CSF remains based on eradication
without vaccination. The issue of the use of deleted vaccines,
offering the possibility to differentiate between infected and
vaccinated animais has been raised. Data currently available
for deleted vaccines do not answer the questions of how to
detect immunotolerant animais and pigs chronically infected
with CSF viruses or whether deleted vaccines offer the same
rapid protection in an emergency situation as presently
available vaccines (7, 5 3 ) . Furthermore, it is uncertain
whether deleted vaccines will offer the same degree of efficacy
(> 100 P D per dose of vaccine). The Scientific Veterinary
Committee of the EU identified several areas for further
investigation, as follows (21):
5 0
- research on safety issues
- development of live marker vaccines in order to boost
The vaccines currently used are produced either using rabbits
(lapinized vaccines) or cell cultures. In both cases the most
widely used strain is the Chinese strain. The efficacy and
safety of this strain have been proven world-wide (29, 3 0 , 4 0 ,
4 5 , 4 9 ) . However, the system of production of the vaccine
may significantly influence safety and efficacy. Vaccines
produced using rabbits pose the problem of the
standardisation of the vaccine viral content. The frequent use
of these vaccines in sows has demonstrated that piglets from
vaccinated sows may react anaphylactically when vaccinated
themselves with lapinised vaccine (6). This problem has been
solved by adapting the Chinese strain to cell culture and by
elimination of all protein of rabbit origin from the final
product. The latter vaccine has been adapted to an ovine
continuous dell line. This vaccine has been scrutinised for
safety in more than 15,000 swine, including pregnant sows,
piglets and fattening swine. Safety of the vaccine has been
confirmed by the use of millions of doses (internai Merial
data).
efficacy
- further testing of marker vaccines in the field of control
- further research on the companion discriminatory test
- further research on vaccination scénarios to be applied in
practice
- economic cost-benefits
- further research on epidemiology of CSF in high density
régions.
Currently, vaccination has been completely discontinued in
countries of the EU. In contrast, the situation in countries in
Asia can be compared with that of the EU before 1 9 8 0 .
Experience and knowledge from both the EU and Asia should
be shared for a better understanding of control measures in
the future. Vaccination is still common practice in several
countries in Central and Eastem Europe.
Vaccination and eradication
The situation in Member States of the EU ten to fifteen years
ago, demonstrates that controlled vaccination and tracing of
movement of pigs are vital steps towards control of the
disease. Vaccination was undertaken under following
conditions:
- high standards of safety and efficacy were maintained
(7, 3 0 )
- vaccines contained at least 100 P D
per dose of vaccine
The vaccine produced on ovine cell line meets the efficacy
requirement (minimum 100 P D
per dose) and is an
interesting tool for controlling the circulation of a virulent
virus (7). This vaccine, with an antigenic content of 4 8 0 P D ,
was able to limit strongly, if not completely, the réplication of
virulent challenge virus in the tonsils, when pigs were infected
oronasally at one week after vaccination performed in piglets
at six weeks old. Long-term immunity using the same vaccine
has been successfully demonstrated (41). This type of vaccine
has been extremely useful in the eradication of CSF in the EU
where vaccination was accompanied by elimination of
infected animais and herds. However, in régions or countries
where a policy of slaughter of infected animais does not exist,
the situation is more complicated, as discussed below.
5 0
5 0
Vaccination in the présence of maternai
antibodies
In an infected environment, sows may have high antibody
titres due to infection with virulent virus. Their offspring may
have higher maternai antibodies than offspring of vaccinated
non-infected sows. In thèse herds, revaccination of piglets is
recommended at the age of nine weeks, or even later in some
cases, because of interference of maternai antibodies with
vaccination at a younger âge. As stated earlier, persistently
infected animais pose an important risk and are difficult to
detect. In a vaccinated environment, thèse animais should be
found and eliminated.
- vaccines were administered under officiai control.
Persistently infected animais: response to
vaccination
In an infected environment, vaccines are the basic tools for
control and eradication. Vaccines can drastically reduce the
circulation of virulent virus and prohibit or significantly
minimise the économie losses due to CSF, on the condition
that the vaccines used meet the highest standards of safety and
efficacy and that administration is correctly performed.
Immunotolerant animais are unlikely to respond to
vaccination (33). Animais that have been chronically infected
with CSF do not always demonstrate a clear antibody
response following a CSF infection. It is not known how thèse
animais react to vaccination, however, chronically infected
pigs shed CSF virus.
5 0
Rev. sci. tech. Off. int. Epiz., 18 (3]
642
The usefulness of precolostral vaccination
Although technically proven, the practicability of precolostral
vaccination is an important obstacle (28, 2 9 ) .
définitive resuit is provided. The number of samples that can
be examined is limited.
Spleen, ileum, mesenteric lymph node, blood, parotis and
tonsil are the most appropriate material for the detection of
virulent and less virulent strains. Virus may be isolated from
Diagnosis
these tissues only two days after exposure. Kidney is also
frequently used for this purpose. Other organs such as skin,
tongue, brain and tonsil are recommended by Pan et al. ( 3 7 ) .
The clinical signs that are typical of CSF consist of petechiae
on the skin, reddening of ear tops, anorexia and fever,
accompanied by central nervous disturbances and diarrhoea.
The incubation period of CSFV is approximately six days.
Early signs, such as anorexia and fever, appear from the
second day after infection. The symptoms of CSF may be
confused with salmonellosis, actinobacillosis, erysipelas,
African swine fever, porcine reproductive and respiratory
syndrome and other diseases. In utero infections may give rise
to abordons, stillbirths and foetal anomalies.
Typical anatomo-pathological lesions are necrotic tonsils,
congested, swollen and haemorrhagic lymph nodes, necrosis
of the ileocaecal valve and petechial haemorrhages in organs
such as the epiglottis, larynx, rénal cortex, urine bladder and
small intestine.
In cases of congenitally persistent infection and chronic CSF,
typical clinical signs as described above may be completely or
partially absent. Symptoms are commonly limited to fever,
anorexia and poor performance. Concurrent infections occur
fairly frequently, which further complicates establishment of a
clinical and pathological diagnosis of CSF. The difference in
clinical signs and pathology between typically virulent strains
and the more chronic type of strains has been described by
Kamolsiriprichaiporn et al. (23, 2 4 ) .
Given the various difficulties in establishing a reliable clinical
and anatomo-pathological diagnosis, laboratory diagnosis is
an essential tool in control of the disease. As mentioned
before, persistently infected animals appear healthy for some
time, although these animais are continuously infecting the
environment. Identification of persistently infected animais is
an important part of ail control measures.
The quality of the antiserum used as conjugate may influence
the results. Monoclonal antibodies are recommended for
immunofluorescence. However, virus is likely to be less easily
isolated from these tissues in the case of less virulent strains
(24). Irrespective of the type of tissue taken, viruses of low
virulence yield less virus per sample than virulent viruses, so
that the risk of false negative results is real. Nevertheless, virus
isolation remains the most reliable, 'gold standard' and the
most useful method to test single animals.
The number of samples that can be examined may be
increased by the use of less labour-intensive enzyme-linked
immunosorbent assay (ELISA). The use of thèse kinds of tests
is based on knowledge of the molecular structure of CSF
virus.
From a molecular point of view, ruminant pestiviruses and
CSFV
are very
closely
related:
three
major
structural
glycoproteins, gp44/48(E ), g p 3 3 ( E ) and g p 5 5 ( E ) have
rns
x
2
been determined in CSFV (42). Thèse are very similar to
analogous glycoproteins determined in ruminant pestiviruses.
Ail pestiviruses share a non-structural protein, p 125/80 (now
commonly
called
NS2-3),
which
represents
the
most
conserved protein within the genus (12). Identical epitopes
are present on p l 2 5
and p80 (NS-3) and monoclonal
antibodies have been produced that react uniformly with
thèse two non-structural proteins (12).
Non-cytopathic pestiviruses only express the non-structural
protein ( p l 2 5 )
(36). Most, if not all, CSF strains are
non-cytopathic and only express the non-structural protein
p l 2 5 . Thèse non-structural proteins are of major importance
as diagnostic tools for pestiviruses in gênerai and CSF in
particular (10, 25, 4 6 ) . Until now, a clear distinction among
Laboratory diagnosis starts with the collection of appropriate
material. The most frequently applied methods are the
fluorescent antibody test on organ sections and virus isolation
in cell culture. Samples should be as fresh as possible and
submitted rapidly to the laboratory. Indeed, if samples are not
fresh, cell destruction may render immunofluorescence on
organ culture difficult or even impossible to perform. If
samples for virus isolation cannot be treated immediately,
they should be frozen immediately after collection. These
techniques are cumbersome and need specialised equipment,
skilled personnel and adapted infrastructure. Multiple
passages are frequently necessary (up to three, one per week)
before virus isolation is positive, causing a long delay before a
pestiviruses as serological groups has not been possible.
Distinctions can only be made with monoclonal antibodies
against different epitopes of these structural proteins ( 2 7 ) .
Extensive pathogenesis studies determined the key role of
persistently infected animais in pestiviruses in cattle (8). The
détection and élimination of persistently infected animais,
followed by vaccination are the main tools for control of
pestiviruses
in
ruminants.
Non-cytopathic
virus
types
typically replicate in cell cultures without showing cytopathic
effect, therefore complicating détection. Persistent infection
results from infection during early pregnancy; when infection
takes place during the first third of pregnancy, the infecting
643
Rev. sci. tech. Off. int. Epiz., 18 (3)
antigen is not recognised as a foreign antigen but as a
self-antigen ( 4 7 ) , thus, no antibodies are developed against
the antigen. The diagnosis of persistently infected, and in
particular, immunotolerant animals can only be achieved by
virus isolation or by detection of the p l 2 5 antigen which is
produced during virus replication.
the only eradication policy that can be applied is the one
based on an effective organisation of reliable and rapid
diagnosis, prompt
declaration
of the
disease
outbreak,
identification of animals and farms and eradication. This
policy is applied in North America, the EU, Australia and New
Zealand. However, in many of these countries vaccination was
an essential part of the control policy prior to obtaining this
The p 1 2 5 antigen detection kit was used by Koenen and
Lefebvre in pigs ( 2 5 ) . Results of a contact challenge
experiment are reported where pigs of different ages were
placed in different degrees of contact with one pig
intramuscularly or intranasally infected with a moderately
virulent strain of CSF. The clinical symptoms of the pigs in
direct contact were more pronounced than pigs in non-direct
contact. Older pigs did not always exhibit clear symptoms of
CSF although the presence of virus could be directly
confirmed by virus isolation as well as indirectly confirmed by
p l 2 5 antigen detection with an ELISA antigen capture test.
Similar results have been described by Lipowski et al. (31)
using a p i 2 5 detection test on blood, leukocytes and organs.
These trials indicate the interest of using the p l 2 5 antigen
capture test. The test is less time-consuming than virus
isolation, easier to perform and particularly indicated for
screening large numbers of animals. In adult animals,
viraemia can be short-lived, therefore sampling of sick
animals and/or animals with fever is highly recommended. In
a vaccinated environment, the p l 2 5 test may be of particular
interest since negative results are obtained for CSF vaccine
produced on an ovine continuous cell line (7), similar to the
results obtained using immunofluorescence at one week after
vaccination (conjugate supplied by the National Veterinary
Institute in Brussels).
high sanitary status. W h e n the number of cases is high, the
price
of
an
eradication
policy
without
vaccination
is
prohibitive.
In highly infected areas, vaccination should be used as the
pivotal part of the control plan, accompanied by an extensive
and effective diagnostic network. Pigs persistently infected
with CSFV
do not always display clear clinical signs,
seroconversion may be absent and high amounts of virus may
be shed over long periods of time. Since these animals may
remain seronegative over long periods, if not for life, a control
based on serological diagnosis alone is questionable. These
virus carriers need to be detected and eliminated. Clinically
sick animals should be tested for CSFV. New diagnostic
techniques based on ELISA, for the detection of CSF antigen
in blood and organs, open up possibilities of testing a high
number of samples in a relatively short time. This should
increase knowledge regarding the infection situation at a herd
and regional level. Furthermore, this testing could enable the
elimination of infected herds to begin while maintaining
vaccination.
Vaccines must be sufficiently potent to reduce the circulation
of virus to the greatest possible extent. Their safety level must
be such that in the case of an emergency, vaccine can be
The p l 2 5 tests detect swine and ruminant pestivirus antigens
which
is
an
advantage
in
an
eradication
administrated to all animals in a herd in a short period of time.
programme.
Ruminant and swine pestiviruses are very closely related and
The combined application of high quality vaccines and the
ruminant pestiviruses can provoke signs very similar to
detection and elimination of chronically or persistently
chronic forms of CSF, particularly in sows infected early
infected animals are crucial for the success of CSF control
during pregnancy ( 3 8 ) . In trying to differentiate between
programmes.
ruminant and swine pestiviruses, extremely precious time
may be lost for the implementation of the appropriate control
measures.
Conclusions
The method of control of CSF will primarily depend on the
disease situation and legislation in the country concerned. In
areas where the disease frequency and/or pig density is low,
Rev. sci. tech. Off. int. Epiz., 18 (3)
644
Peste porcine classique : l'expérience européenne
et un guide pour les régions infectées
J. Vandeputte & G. Chappuis
Résumé
La peste porcine classique reste un problème mondial, du fait de ses
conséquences directes sur la production porcine lorsque la maladie est
enzootique ou épizootique et du fait de la menace qu'elle représente lorsque la
maladie a déjà été éradiquée.
Les auteurs rappellent les caractéristiques de cette maladie. Une attention
particulière est portée à sa forme chronique, parce qu'elle semble poser des
problèmes notamment durant les stades finaux des programmes d'éradication.
Au début des années 1980, les États membres de l'Union européenne (UE) se
répartissaient en deux groupes : ceux qui ne pratiquaient plus la vaccination et
qui étaient en même temps indemnes d'infection (c'est-à-dire officiellement
indemnes de la maladie) et ceux où la vaccination était soit autorisée soit
obligatoire. Afin de permettre le libre échange entre les différents États membres,
un plan d'éradication fut mis au point au niveau de l'UE. Initialement, le plan
combinait la vaccination avec la souche chinoise du virus et l'éradication
(abattage sanitaire). Dès que le taux d'infection était tombé à un niveau
suffisamment bas, la vaccination était abandonnée et le contrôle de la maladie
visait uniquement à l'éradication (par abattage sanitaire). Le Royaume-Uni,
l'Autriche, le Danemark, l'Irlande, le Luxembourg, la Finlande et la Suède avaient
déjà arrêté la vaccination avant 1980. Dans les autres pays, la vaccination a
permis de contrôler les dernières épidémies avant d'être finalement
abandonnée : en France en 1983, aux Pays-Bas en 1986, en Belgique, en Espagne
et en Grèce en 1988, en Allemagne en 1989 et en Italie en 1990. Depuis, aucune
vaccination contre la peste porcine classique n'a été pratiquée dans l'UE.
De nouvelles techniques de diagnostic, par exemple l'épreuve immunoenzymatique pour la détection de l'antigène p125 du virus, ont prouvé leur utilité
dans la détection précoce d'animaux infectés.
Pour les zones enzootiques, la vaccination avec la souche chinoise semble
extrêmement efficace. Des vaccins contenant au minimum 100 P D de virus par
dose sont capables de limiter de façon significative la réplication du virus
sauvage au niveau des amygdales, ce qui réduit considérablement la diffusion du
virus dans l'environnement. Dans les régions très infectées, la vaccination joue
un rôle crucial. L'expérience européenne montre qu'il est possible d'éradiquer la
maladie si l'emploi de vaccins d'une grande efficacité est accompagné d'une
bonne identification des porcs qui permette le contrôle des mouvements des
animaux, d'un système de diagnostic précoce et d'une élimination rapide des
troupeaux infectés.
50
Mots-clés
Diagnostic - Immunotolérance - Peste porcine classique - Pestivirus - Porcs - Union
européenne - Vaccination - Virus.
645
Rev. sci. tech. Off. int. Epiz., 18 (3]
Peste porcine clásice: experiencia europea y guía para zonas
infectadas
J. Vandeputte & G. Chappuis
Resumen
La peste porcina clásica sigue constituyendo un problema en todo el mundo,
tanto por sus repercusiones directas sobre la producción porcina, en zonas
donde la enfermedad es epidémica o enzoótica, como por la amenaza que supone
en zonas donde ya ha sido erradicada.
Los autores repasan las características generales de la enfermedad,, haciendo
hincapié en su forma crónica, que plantea problemas sobre todo en las etapas
finales de los programas de erradicación.
A principios de los años 1980, los Estados Miembros de la Unión Europea (UE) se
repartían en dos grupos: países donde no se practicaban vacunaciones y que
estaban libres de infección (esto es, países oficialmente libres de la enfermedad);
y países donde se permitía u obligaba a vacunar a los animales. Con el fin de
hacer posible el libre comercio entre todos los países de la UE, se implemento un
plan de erradicación. En su primera fase, el plan combinaba campañas de
vacunación (con la cepa china del virus) con campañas de erradicación
(sacrificio sanitario de los rebaños infectados). Posteriormente, cuando la tasa de
rebaños infectados cayó a un nivel lo bastante bajo, se abandonaron las
vacunaciones para fiar la lucha contra la peste porcina clásica exclusivamente a
la erradicación (sacrificio sanitario). El Reino Unido, Austria, Dinamarca, Irlanda,
Luxemburgo, Finlandia y Suecia ya habían interrumpido las vacunaciones antes
de 1980. Los demás países continuaron con sus campañas a fin de controlar los
últimos brotes epidémicos, y después fueron interrumpiéndolas progresivamente
en el orden siguiente: Francia en 1983, Países Bajos en 1986, Bélgica, España y
Grecia en 1988, Alemania en 1989 e Italia en 1990. A partir de 1990 no se han
realizado vacunaciones contra la peste porcina clásica en el seno de la UE.
Nuevas técnicas de diagnóstico de la peste porcina clásica, como el ensayo
inmunoenzimático para la detección del antígeno p125 del virus, han demostrado
ser de gran utilidad para la detección precoz de animales infectados.
En zonas donde la enfermedad es endémica, el uso de vacunas con la cepa china
parece sumamente eficaz. Las vacunas con un mínimo de 100 P D de virus por
dosis son capaces de contener de forma significativa la replicación del virus
virulento en las amígdalas, lo que reduce considerablemente la excreción de
virus y su difusión en el entorno. En zonas con elevada tasa de infección, las
vacunaciones desempeñan un papel crucial. La experiencia europea demuestra
que es posible erradicar la enfermedad combinando el uso de vacunas de gran
eficacia con una identificación eficiente de los animales que permita controlar
sus desplazamientos, establecer un sistema de diagnóstico precoz y eliminar con
rapidez los rebaños infectados.
5 0
Palabras clave
Diagnôstico - Inmunotolerancia - Peste porcina clâsica - Pestivirus - Porcinos - Union
Europea - Vacunaciôn - Virus.
•
Rev. sci. tech. Off. int. Epiz., 18 (3)
646
References
1.
2.
European
Economic
Swine Fever Laboratories, 1 6 - 1 7 J u n e , Vienna. Commission
Directive
80/217/EEC
of the European Communities, Vienna, W 7 8 8 8 / 9 7 , 1 - 8 4 .
Community measures for the control of classical swine fever,
Anon. ( 1 9 9 7 ) . - Report on the Annual Meeting of National
Fever
Laboratories,
9 - 1 0 July,
Birmingham.
15.
Anon.
(1998).
-
Untersuchungen
zu
1993-1995/Abschlussbericht z u m
16.
European
Economic
Community
(1980).
-
Council
Aubert M., Picard M., Fouquet E., Conde J . , Crucière C ,
Ferry R., Albina E., Barrat J . & Vedeau F. ( 1 9 9 4 ) . - La peste
L 3 2 5 , 5-7.
17.
European
Economic
Community
(1980).
-
Council
Directive 80/1098/EEC of 11 November 1 9 8 0 amending
Bendixen H J . ( 1 9 8 8 ) . - Control of classical swine fever. In
Directive 64/432/EEC with regard to swine vesicular disease
Classical swine fever and related viral infections (B. Liess,
and classical swine fever. Off. ]. Eur. Communities,
ed.). Martinus Nijhoff Publishing, Boston, 2 1 7 - 2 3 2 .
11-13.
Biront P., De Roose P.J. & Leunen J . ( 1 9 7 9 ) . - Anaphylaxis
18.
Economic
Community
(1980).
a virulent strain of classical swine fever virus. Vet. Microbiol.,
and classical swine fever. Off. ]. Eur. Communities,
T h e pathways
for bovine
19.
European
Economic
Community
(1980).
-
Council
Directive 80/1101/EEC of 11 November 1 9 8 0 amending
virus
diarrhoea virus biotypes in the pathogenesis of disease. Arch.
Virol. ( S u p p l ) , 3 , 7 9 - 9 6 .
and classical swine fever. Off.]. Eur. Communities, L 3 2 5 , 1 6 .
20.
Cheville N.F. & Mengeling W . L . ( 1 9 6 9 ) . - The pathogenesis
21.
Rodriguez
A.,
22.
genetic typing of classical swine fever virus isolates from
Germany. J . virol Meih., 7 5 , 1 4 1 - 1 5 0 .
persistence. Dtsch. fierârtzti. Wochenschr., 1 0 2 , 3 7 9 - 3 8 4 .
of
an
international
reference
panel
Greiser-Wilke I., Depner K., Fritzemeier J . , Haas L. &
Moennig V. ( 1 9 9 8 ) . - Application of a computer program for
wild boar (Sus seroja) - experimental infections and viral
Edwards S., Moennig V. & Wensvoort G. ( 1 9 9 1 ) . - T h e
European Union ( 1 9 9 7 ) . - Outcome of discussions. T h e use
2 4 Scientific Veterinary Committee, Brussels, 1 - 1 0 .
Bickhardt K. & Liess B. ( 1 9 9 5 ) . - Classical swine fever in
development
23.
of
Kamolsiriprichaiporn
S., Hooper P.T., Morrissy
monoclonal antibodies for the differentiation o f hog cholera
of
pathological studies. Aust. vet.J., 6 9 , 2 4 0 - 2 4 4 .
Immunological aspects of the
infection. In Classical swine fever and related viral infections
e d . ) . Martinus
Nijhoff
Publishing,
Boston,
C.J. &
Westbury H.A. ( 1 9 9 2 ) . - A comparison of the pathogenicity
virus from other pestiviruses. Vet. Microbiol., 2 9 , 1 0 1 - 1 0 8 .
Ehrensperger F. ( 1 9 8 8 ) . -
Council
particular, classical swine fever. Report o f the Scientific
Rev. sci. !ech. Off. int. Epiz., 1 2 ( 2 ) , 4 8 3 - 4 9 2 .
A.,
-
80/217/EEC
Veterinary Committee, 17 September. General Directorate
in Biotechnology applied to the diagnosis of animal diseases.
Gruber
(1980).
of marker vaccines in the control of infectious diseases in
cattle, persistently infected with bovine virus diarrhoea virus,
A.,
Community
swine fever, 11/11/1980. Off.J. Eur. Communiües, L 3 2 5 , 1 7 .
Renard A. ( 1 9 9 3 ) . - Five hours to identify immunotolerant
K.R., Müller
Economic
introducing Community measures for the control of classical
261-274.
Crevât D . , Vandenbergh D., Chappuis G., Lecomte C. &
European
Directive 80/1100/EEC, amending Directive
of chronic hog cholera (swine fever). Lab. invest., 2 0 ,
143-163.
L325,
Directive 80/215/EEC with regard to swine vesicular disease
Brownlie J . ( 1 9 9 1 ) . -
Liess,
Council
14-15.
14, 105-113.
(B.
-
Directive 80/1099/EEC of 11 November 1 9 8 0 amending
Biront P., Leunen J . & Vandeputte J . ( 1 9 8 7 ) . - Inhibition o f
Depner
European
L325,
Directive 72/461/EEC with regard to swine vesicular disease
with a Chinese strain vaccine and challenged oronasally with
13.
Council
Directive 80/1096/EEC: Council Decision o f 11 November
• virus replication in the tonsils of pigs previously vaccinated
12.
-
Communities, L 3 2 5 , 1-4.
Tijdschr., 4 8 , 4 8 4 - 4 9 7 .
11.
(1980).
1 9 8 0 introducing Community financial measures for the
of piglets after hog cholera vaccination. Vlaams diergeneesk.
10.
Community
eradication o f classical swine fever. Off. ]. Eur. Communities,
239-247.
9.
Economic
Community free from classical swine fever. Off. J. Eur.
Vorkommen,
porcine classique du sanglier en Europe. Ann. Méd. vét, 1 3 8 ,
8.
European
conditions designed to render and keep the territory o f the
Veterinary School, Hanover, 1 - 5 0 .
7.
Council
1-56.
(KSP) in Deutschland
6.
-
1 9 8 0 introducing
Directive 80/1095/EEC of 11 November 1 9 8 0 laying down
Forschungsprojekt 9 6 H S 0 2 2 . Institute of Virology, Hanover
5.
(1980).
of 2 2 January
Commission of the European Communities, VI/8857/98,
Austbreitung und Bekämpfung der klassischen Schweinepest
4.
Community
21/2/1980. Off. J. Eur. Communiües, L 4 7 , 1 1 - 2 3 .
Anon. ( 1 9 9 8 ) . - Report on the Annual Meeting of National
Swine
3.
14.
24.
two strains
o f hog cholera
virus.
1 : clinical and
Kamolsiriprichaiporn S., Morrissy C.J. & Westbury H.A.
( 1 9 9 2 ) . - A comparison of the pathogenicity o f two strains of
hog cholera virus. 2: virological methods. Aust. vet. ]., 6 9 ,
245-248.
647
Rev. sci. tech. Off. int. Epa.. 18 (3)
25.
Koenen
F.
<Sr Lefebvre
J.
(1995).
-
Kinetics
of an
39.
( 1 9 9 5 ) . - Der Schweinepest-seuchenzug 1993/94, Probleme
field isolate. Immunobiology of viral infections, In Proc.
und Konsequenzen. Tierarztl. Umsch., 5 0 , 5 2 2 - 5 3 0 .
3 r d Congress o f the European Society o f Veterinary Virology,
4-7
September
1994,
Interlaken.
Marcel
Mérieux
40.
Koenen
F.,
Van
Caenegem
G.,
Vermeersch
J.P.,
Epidemiological
characteristics of an outbreak of classical swine fever in an
le porc à l'engrais. Rev. Méd. vét, 1 2 4 , 1 8 1 - 1 8 9 .
41.
Kosmidou A., Ahl R., Thiel H.J. & Weiland E. ( 1 9 9 5 ) . Differentiation of classical swine fever virus (CSFV) strains
monoclonal
antibodies
against
Dis., 6 , 2 8 1 - 2 8 9 .
42.
structural
29.
Lai S.S., Ho W . C . & Tsao S.H. ( 1 9 8 6 ) . - Absorption of
(Suppl), 3 , 7 - 1 8 .
43.
Noordhuizen J . P . T . M . & Goedzeels V. ( 1 9 9 6 ) . - Simulation
cholera. J . Chin. Soc. vet. Set, 1 2 , 1 1 7 - 1 2 3 .
studies
using
International
an attenuated
Pig
virus,
Veterinary
LPC-China
Society,
strain.
44.
fever vaccines
to prevent
virus
carriers
in the
45.
Terpstra C. ( 1 9 7 7 ) . - D e immuniteit tegen besmetting met
vaccinated pigs, after contact with field virus. Arch, experim.
varkenspestvirus
VetMed., 3 1 , 5 3 3 - 5 3 6 .
geënte zeugen. Tijdschr. Diergeneeskd., 1 0 2 , 1 2 9 3 - 1 2 9 8 .
Lipowski A., Pejsak Z., Thibault J . C . & Crevat D. ( 1 9 9 6 ) . Veterinary
Society
(IPVS),
Faculty
of
46.
van biggen
geboren
uit met C-vaccin
Thibault J . - C , Crevât D. & Chappuis G. ( 1 9 9 3 ) . - Control of
bovine virus diarrhoea-mucosal disease in cattle: examples o f
Veterinary
the c o m b i n e d use o f serological screening, viral antigen
detection and vaccination. In Biotechnology applied to the
diagnosis of animal diseases. Rev. sci. tech. Ojj. int.
Lowings J . P . , Patón D.J., Sands J . J . , D e Mia G.M. & Rutili D.
(1994).
-
Classical
swine
fever:
genetic
detection and
Matile E. ( 1 9 8 9 ) . - Untersuchung zur Immunotoleranz von
Ferkeln
gegenüber
dem
Virus
der
Europäischen
47.
Tizard I. ( 1 9 9 2 ) . - Veterinary immunology: an introduction,
4th
E d . W . B . Saunders,
Harcourt
Brace
Jovanovich,
Philadelphia, 2 0 3 - 2 1 5 .
48.
Vannier P., Plateau E. & Tillon J . P . ( 1 9 8 1 ) . -
Congenital
tremor in pigs farrowed from sows given h o g cholera virus
Schweinepest (ESP). Inaugural-Dissertation zur Erlangung
during pregnancy. Am. j. vet. Res., 4 2 , 1 3 5 - 1 3 7 .
der Doktorwürde der Veterinärmedizinische Fakultät der
Universität Zürich, Zentralstelle der Studentenschaft, Zurich,
Epiz,
12 (2), 4 7 1 - 4 8 1 .
75, 3461-3468.
49.
Van Oirschot J . T . ( 1 9 9 2 ) . - H o g cholera in diseases of swine,
55 pp.
7th
Mengeling W . L . & Packer R.A. ( 1 9 6 9 ) . - Pathogenesis of
S. D'Allaire & D.J. Taylor, eds). Wolfe Publishing, London,
chronic h o g cholera: host response. Am. J . vet. Res., 3 0 ,
274-285.
409-417.
50.
Ed.
(A.D. Leman,
B.D. Straw,
W.L.
Mengeling,
Van Oirschot J . T . & Terpstra C. ( 1 9 7 7 ) . - A congenital
Mesplede A. & Albina E. ( 1 9 9 7 ) . - Le point sur la peste
persistent swine fever infection. I: Clinical and virological
porcine classique : epidemiologie et contrôle. Point vêt, 2 8 ,
observations. Vet. Microbiol, 2 , 1 2 1 - 1 3 2 .
25-35.
51.
Moennig V. ( 1 9 9 2 ) . - T h e hog cholera virus. Comp. Immunol.
Microbiol, inject. Dis., 1 5 , 1 8 4 - 2 0 1 .
Pan I.C., Huang T . S . , Pan C H . , Chern S.-Y., Lee S.-H.,
Chiù S.Y., Chang J . S . , Hue D.K., Lee H . C & Chang C.N.
( 1 9 9 3 ) . - T h e skin, tongue, and brain as favorable organs for
h o g cholera diagnosis by immunofluorescence. Arch. Virol.,
131,475-481.
Paton D.J. & Done S.H. ( 1 9 9 4 ) . - Congenital infection of
pigs with ruminant-type Pestiviruses. J . comp. Pathol, 1 1 1 ,
151-163.
Vanthemsche P. ( 1 9 9 6 ) . - Classical swine fever 1 9 9 3 - 1 9 9 4
Belgium. Pig]., 3 7 , 4 3 - 5 3 .
52.
Vanthemsche P. & Saegerman C. ( 1 9 9 4 ) . - Gestion d'un
épisode de peste porcine classique en Belgique.
Lin Y.L., Huang B.Y., Lin C.C., Li N.J., Lin J . P . , Yang Y.H.,
38.
Stadejek T., W a r g J . & Ridpath J . F . ( 1 9 9 6 ) . - Comparative
swine fever virus strains from Europe, Asia and America.
analysis of differences between virus isolates. J . gen. Virol.,
37.
national
Arch. Virol, 1 4 1 , 7 7 1 - 7 7 7 .
104.
36.
of
sequence analysis of the 5 ' noncoding region of classical
Medicine, University o f Bologna, 7 - 1 0 July. IPVS, Bologna,
35.
impact
systems on the control o f
Copenhagen. Reproset, Copenhagen, 1 3 3 .
Pig
34.
epidemiological
classical swine fever in Belgium. Prev. vet. Med., 2 6 , 1 1 9 - 1 3 2 .
3 0 J u n e - 3 July,
Early detection o f h o g cholera virus infection. International
33.
the
Leunen J . & Strobbe R. ( 1 9 7 7 ) . - Capacity of attenuated
swine
32.
on
identification and recording
Lee R.C.T., W a n g J . T . , Lai S.S., W u F . M . & Lin T . T . C .
cholera
31.
Saatkamp H . W . , Dijkhuizen A.A., Geers R., Huirne R.B.M.,
colostral antibodies and neonatal vaccination against h o g
( 1 9 8 0 ) . - Studies on precolostral vaccination against h o g
30.
Rumenapf T., Meyers G., Stark R. & Thiel H.J. ( 1 9 9 1 ) . Molecular characteristics of h o g cholera virus. Arch. Virol.
glycoproteins. Vet. Microbiol, 4 7 , 1 1 1 - 1 1 8 .
28.
Precausta P., Kato F. & Brun A. ( 1 9 8 3 ) . - Swine fever
immunisation of piglets. Comp. Immunol. Microbiol. inject.
area o f high pig density. Vet. R e e , 1 3 9 ( 1 5 ) , 3 6 7 - 3 7 1 .
using
obtenue sur culture
cellulaire. Innocuité - diffusibilité - durée d'immunité chez
Vandenheede J . & Deluyker H. ( 1 9 9 6 ) . -
27.
Precausta P., Perrenot F. & Jost P. ( 1 9 7 3 ) . - Souche chinoise
CL du virus de la peste porcine
Foundation, Lyons, France, 3 2 2 - 3 2 6 .
26.
Pittler H., Fiedler J . , J e n t s c h D . , Hasselbach P. & Kramer M.
experimental infection with a classical swine fever ( C S F )
Epidemiol
Santé anim., 2 6 , 2 9 - 4 1 .
53.
W i t t m a n n W . ( 1 9 9 4 ) . - Gedanken zur Bekämpfung der
Europäischen Schweinepest in Deutschland. Prallt. Tierarzt.,
4, 337-340.